Last reviewed · How we verify
oleum neutralicum
Mechanism of action unknown; product appears to be a vitamin D3 formulation studied in hematologic malignancies.
Oleum neutralicum is a discontinued investigational product developed by Semmelweis University with unclear pharmacological classification and mechanism. The compound was evaluated in a Phase 3 clinical trial examining vitamin D3 substitution effects in patients with chronic lymphoid leukemia and other hematologic malignancies, which was terminated early with only 31 enrolled patients. No FDA approval was ever granted, no regulatory pathway was completed, and the product appears to have been abandoned prior to commercialization. The lack of published clinical data, molecular characterization, and regulatory documentation suggests this was an early-stage academic research initiative that did not advance to market. Given the discontinued status and absence of commercial development, oleum neutralicum holds no current clinical or commercial significance in the pharmaceutical landscape.
At a glance
| Generic name | oleum neutralicum |
|---|---|
| Sponsor | Semmelweis University |
| Drug class | Unknown; possibly vitamin D analog or immunomodulator |
| Target | Unknown; possibly vitamin D receptor (VDR) if vitamin D3-based |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Oleum neutralicum was investigated as a potential therapeutic agent in a clinical trial focused on vitamin D3 substitution in patients with malignant and immune-hematologic diseases, specifically chronic lymphoid leukemia. The exact mechanism of action, molecular target, and pharmacological class remain undocumented in available scientific literature and regulatory filings. The trial design suggests the investigator hypothesized that vitamin D3 supplementation might provide therapeutic benefit in hematologic malignancies, possibly through immunomodulatory or anti-proliferative pathways, but no published results or mechanistic data are available to confirm this.
Approved indications
Pipeline indications
- Chronic lymphoid leukemia with vitamin D3 substitution — Phase 3
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oleum neutralicum CI brief — competitive landscape report
- oleum neutralicum updates RSS · CI watch RSS
- Semmelweis University portfolio CI